PDF(Pubmed)
Abstract：
UNASSIGNED: Neuromyelitis optica spectrum disorder (NMOSD) is a devastating inflammatory disease of the central nervous system that is often severely disabling from the outset. The lack of pathognomonic aquaporin 4 (AQP4) antibodies in seronegative NMOSD not only hinders early diagnosis, but also limits therapeutic options, in contrast to AQP4 antibody-positive NMOSD, where the therapeutic landscape has recently evolved massively.
UNASSIGNED: We report a 56-year-old woman with bilateral optic neuritis and longitudinally extensive myelitis as the index events of a seronegative NMOSD, who was successfully treated with inebilizumab.
UNASSIGNED: Treatment with inebilizumab may be considered in aggressive seronegative NMOSD. Whether broader CD19-directed B cell depletion is more effective than treatment with rituximab remains elusive.
UNASSIGNED: We report a 56-year-old woman with bilateral optic neuritis and longitudinally extensive myelitis as the index events of a seronegative NMOSD, who was successfully treated with inebilizumab.
UNASSIGNED: Treatment with inebilizumab may be considered in aggressive seronegative NMOSD. Whether broader CD19-directed B cell depletion is more effective than treatment with rituximab remains elusive.
摘要：
视神经脊髓炎谱系障碍(NMOSD)是中枢神经系统的破坏性炎性疾病,其通常从一开始就严重致残。血清阴性NMOSD中缺乏病理水通道蛋白4（AQP4）抗体不仅阻碍了早期诊断，但也限制了治疗选择，与AQP4抗体阳性NMOSD相反，治疗景观最近大规模发展。
我们报告了一名56岁的女性，患有双侧视神经炎和纵向广泛脊髓炎，这是血清阴性NMOSD的指标事件，谁是成功的治疗与纤珠单抗。
■在侵袭性血清阴性NMOSD中，可以考虑用异胆珠单抗治疗。更广泛的CD19指导的B细胞清除是否比利妥昔单抗治疗更有效仍然难以捉摸。
我们报告了一名56岁的女性，患有双侧视神经炎和纵向广泛脊髓炎，这是血清阴性NMOSD的指标事件，谁是成功的治疗与纤珠单抗。
■在侵袭性血清阴性NMOSD中，可以考虑用异胆珠单抗治疗。更广泛的CD19指导的B细胞清除是否比利妥昔单抗治疗更有效仍然难以捉摸。
